Posted by Michael Wonder on 27 Jun 2022
FDA approves treatment for chronic weight management in certain paediatric patients aged 12 years and older
27 June 2022 - The U.S. FD has approved a supplemental indication for Qsymia (phentermine and topiramate extended-release capsules) for chronic weight management in paediatric patients aged 12 years and older who are obese, defined as a body mass index of 95th percentile or greater when standardised for age and sex.
Qsymia should be used as additional therapy to reduced calorie diet and increased physical activity.
